


I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on September 11, 2000.

  
Attorney for Applicant(s)

9/11/2000  
Date of Signature

13  
10/4/00

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: JAMES D. MARKS and PETER AMERSDORFER

Assignee: The Regents of the University of California

Title: THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS


Serial No.: 09/144,886

Filing Date: August 31, 1998

Examiner: L. Lee

Art Unit: 1645

Docket No.: M-8951US



COMMISSIONER FOR PATENTS  
Washington, D. C. 20231

**AMENDMENT**

Sir:

In response to the Office Action dated March 10, 2000, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks. A Change in Correspondence Address and a petition to extend the period of response for three months is enclosed. For the convenience of the Examiner, a list of the pending claims is attached as Appendix I.

**In the Claims:**

Please cancel claims 44-77 without prejudice.

Please amend claims 1 and 24 as follows:

1. (Once amended) An isolated single-chain antibody that specifically binds to an epitope specifically bound by an antibody expressed by a clone selected from the group consisting of clone S25, clone C25, clone C39, clone 1C6, and clone 1F3, wherein said antibody binds to and neutralizes botulinum neurotoxin type A (BoNT/A).

B'